A Phase II Study of Olaparib in Recurrent IDH-mutant High Grade Gliomas OLAGLI
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2019
Price : $35 *
At a glance
- Drugs Olaparib (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Acronyms OLAGLI
- 22 Mar 2019 Planned End Date changed from 1 Jun 2021 to 20 Sep 2021.
- 22 Mar 2019 Planned primary completion date changed from 1 Jun 2020 to 20 Sep 2020.
- 22 Mar 2019 Status changed from not yet recruiting to recruiting.